Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK127
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AK127 is a humanized IgG1 kappa monoclonal antibody that targets TIGIT (T cell immunoreceptor with Ig and ITIM domains), an immune checkpoint receptor expressed on various immune cells including tumor-infiltrating lymphocytes and natural killer (NK) cells. By binding to TIGIT, AK127 blocks its interaction with ligands such as CD112 and CD155, thereby relieving immune suppression in the tumor microenvironment and promoting anti-tumor immunity. The drug is being developed by Akeso Biopharma for the treatment of advanced solid tumors, including use in combination therapies. Its mechanism of action includes antibody-dependent cellular cytotoxicity as well as stimulation of NK cells and T lymphocytes[1][2][3][4][6][7].
- Other names
- Akeso/CTTQ-TIGITAkeso TIGITTIGIT monoclonal antibody
02
Targets
TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on AK127.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK127.